Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells

Neoplasia

Volumn 13, Issue 9, 2011, Pages 784-791

  Sampetrean, Oltea ^a,b   Saga, Isako ^a   Nakanishi, Masaya ^a,c   Sugihara, Eiji ^a,b   Fukaya, Raita ^a   Onishi, Nobuyuki ^a   Osuka, Satoru ^a,d   Akahata, Masaki ^a,e   Kai, Kazuharu ^a   Sugimoto, Hachiro ^c   Hirao, Atsushi ^f   Saya, Hideyuki ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e TOHO UNIVERSITY   (Japan)

^f KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN H RAS; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARF GENE; ARTICLE; BRAIN HEMORRHAGE; BRAIN TUMOR INITIATING CELL; BREAST NECROSIS; CARCINOGENESIS; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GLIOBLASTOMA; HISTOPATHOLOGY; HOST CELL; INK4A GENE; MALE; MOUSE; NERVE TRACT; NEURAL STEM CELL; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; SURVIVAL TIME; TRANSGENICS; TUMOR CELL; TUMOR GROWTH;

EID: 80053452975     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11624     Document Type: Article

References (30)

1. Holland EC (2001). Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2, 120-129.
2. Kamnasaran D (2009). Stem cells and models of astrocytomas. Clin Invest Med 32, E166-E179.
3. de Vries NA, Beijnen JH, and van Tellingen O (2009). High-grade glioma mouse models and their applicability for preclinical testing. Cancer Treat Rev 35, 714-723.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
5. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, and Fuller GN (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25, 55-57.
6. Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, and Parada LF (2009). Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15, 45-56.
7. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, Cordon-Cardo C, Teruya-Feldstein J, and Pandolfi PP (2005). Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278-285.
8. Morita S, Kojima T, and Kitamura T (2000). Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 7, 1063-1066.
9. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
10. Schmidt EE, Ichimura K, Reifenberger G, and Collins VP (1994). CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54, 6321-6324.
11. Guha A, Feldkamp MM, Lau N, Boss G, and Pawson A (1997). Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15, 2755-2765.
12. Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, and Guha A (2005). Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 167, 859-867.
13. Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, Ohmura M, Shugo H, Ooshio T, Nakada M, et al. (2009). Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci USA 106, 17163-17168.
14. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, and Holland EC (2002). Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62, 5551-5558.
15. Friedl P and Gilmour D (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10, 445-457.
16. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, and Ohgaki H (1997). Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 94, 303-309.
17. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, et al. (2009). A network model of a cooperative genetic landscape in brain tumors. JAMA 302, 261-275.
18. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, and Dirks PB (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828.
19. Huse JT and Holland EC (2010). Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10, 319-331.
20. Reya T, Morrison SJ, Clarke MF, and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
21. Cayre M, Canoll P, and Goldman JE (2009). Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol 88, 41-63.
22. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97, 12846-12851.
23. Ehtesham M, Yuan X, Kabos P, Chung NH, Liu G, Akasaki Y, Black KL, and Yu JS (2004). Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 6, 287-293.
24. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A, and Guha A (2001). Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61, 3826-3836.
25. Matsukado Y, Maccarty CS, and Kernohan JW (1961). The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 18, 636-644.
26. Arita N, Taneda M, and Hayakawa T (1994). Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126, 84-92.
27. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906.
28. Friedl P and Wolf K (2008). Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68, 7247-7249.
29. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, and Canoll P (2006). Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 53, 799-808.
30. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, et al. (2008). Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26, 5610-5617.